A team from the Swedish Karolinska Institutet has developed a strategy to preferentially target nondividing cells in nutrient-poor tumor regions by attacking their mitochondrial function. Classical chemotherapies target rapidly dividing cells, but not all tumor cells are dividing rapidly at any given time.